Baseline (90 min) | After 60 min hypertonic saline infusion (150 min) | 90 min post hypertonic saline infusion (210 min) | P-value (difference in response) | |
---|---|---|---|---|
p-AVP (ng/L) | ||||
Placebo | 0.20 (0.20;0.20) | 0.50(0.40;0.70)* | 0.20(0.20;0.23) | < 0.001 |
Furosemide | 0.20 (0.18;0.20) | 0.90(0.60;1.10)*,† | 0.30(0.20;0.40)*,† | |
PRC (ng/L) | ||||
Placebo | 9.0 (5.3;13.0) | 7.3 (4.4;10.9)* | 5.6 (2.9;7.4)* | 0.001 |
Furosemide | 10.3 (5.8;16.9) | 9.3 (7.7;16.2)† | 8.0 (5.3;19.3)† | |
p-AngII (ng/L) | ||||
Placebo | 12 (8;18) | 7 (5;13)* | 6 (4;11) * | 0.014 |
Furosemide | 16 (9;22) | 16 (11;20)† | 16 (9;24)† | |
p-Aldo (pmol/L) | ||||
Placebo | 240 (200;342) | 167 (144;211)* | 169 (161;213)* | 0.001 |
Furosemide | 277 (232;377) | 256 (228;328)† | 262 (201;325)† |